Millions of Britons, particularly the most vulnerable in their society, probably breathed a sigh of relief on Tuesday when NHS leaders introduced the first patient to receive a dose of the still-experimental Pfizer-BioNTech vaccine: A 90-year-old woman on the cusp of her 91st birthday who said she is thrilled she’ll be able to spend the holiday with family without fear. Adding to the media interest, patient No. 2 was a man, 81, named “William Shakespeare”.
One day later, after a week where leading vaccine developers like Pfizer and Moderna warned about supply constraints, hinting that they’re widely touted projections might be unrealistic, and forcing President Trump to sign an executive order to try and ensure American patients are treated as a priority, the Britain’s pharma regulator has dropped a bombshell warning.
The MHRA (Britain’s regulator) warned Wednesday that any patients with histories of having “powerful allergic overreactions” should avoid the vaccine. For a report published by a professional news agency like Reuters, the details were surprisingly vague. Since a huge number of Americans are allergic to something, a little more clarity would be appreciated.
As someone who has many allergies, I wish we had more info on which allergens were an issue. “any person with a history of significant allergic reactions to vaccines, medicine or food should not receive the Pfizer/BioNTech vaccine.” https://t.co/ja6SNtiEbA
— dubious flirtation (@chickie_tendi) December 9, 2020
According to public opinion polls, state and federal health officials have apparently been succeeding in establishing “credibility” to these vaccines. But there’s no question that setbacks like this could have a profound affect on individuals’ willingness to accept the vaccine, which also reportedly comes with punishing sideeffects. – READ MORE
Listen to the insightful Thomas Paine Podcast Below --